Antiepileptic drug treatment: Outcomes and adherence

Pharmacotherapy

Volumn 20, Issue 8 II, 2000, Pages

  Garnett, W R ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

CAREGIVER; CONFERENCE PAPER; COST; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HEALTH CARE QUALITY; HUMAN; PATIENT SATISFACTION; QUALITY OF LIFE;

EID: 0033868589     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.12.191s.35250     Document Type: Conference Paper

References (68)

1. Contemporary diagnosis and management of the patient with epilepsy
2. Epilepsy, A Report to the Nation
3. Descriptive epidemiology of epilepsy: Contributions of population-based studies from Rochester, Minnesota
4. Definition and overview of intractable epilepsy
5. Determinants of mortality in status epilepticus
6. Development of the Quality of Life in Epilepsy inventory
7. Cognitive side-effects of chronic antiepileptic drug treatment: A review of 25 years of research
8. Acute and chronic toxicity of antiepileptic medications: A selective review
9. Patient-validated content of epilepsy-specific quality-of-life measurement
10. Cost of epilepsy in the United States: A model based on incidence and prognosis
11. Cost of refractory epilepsy in adults in the USA
12. Payer costs of patients diagnosed with epilepsy
13. Patients with refractory seizures
14. Commission on Outcome Measurement in Epilepsy, 1994-1997: Final report
15. Outcomes for P and T committees: Where are we going?
16. The role of outcomes in quality assessment and assurance
17. Measuring and managing health care quality procedures, techniques, and protocols
18. Opportunities and responsibilities in pharmaceutical care
19. Surgery for seizures
20. Consensus guidelines: Preconception counseling, management, and care of the pregnant woman with epilepsy
21. Relationship between knowledge of epilepsy (KE) and quality of life (QOL) in patients with epilepsy
22. Assessing the spectrum of antiepileptic drug use and compliance in a community setting
23. Factors influencing compliance with antiepileptic drug regimes
24. Emergency medical services: Seizure protocol
25. A comparison of rectal diazepam gel and placebo for acute repetitive seizures
26. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery
27. Phenobarbital
28. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures
29. Inhibition of epoxide hydrolase by valproic acid in epileptic patients receiving carbamazepine
30. Effect of felbamate on carbamazepine and its major metabolites
31. Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations
32. Effect of antacids on phenytoin bioavailability
33. Antiepileptic drugs. A review of clinically significant drug interactions
34. Neuropharmacology and drug interactions in clinical practice
35. Overview of health-related quality-of-life measures
36. Adjunctive therapy in epilepsy: A cost effective comparison of two AEDs
37. Cost effectiveness model of adjunctive lamotrigine for the treatment of epilepsy
38. An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy
39. Cost of treating mental illness from a managed care perspective
40. Formulary decisions and health economics
41. Methods for measuring patient satisfaction with specific medical encounters
42. The Kaiser Permanente/USC Patient Consultation Study: Patient satisfaction with pharmaceutical services
43. Antiepileptic drugs as a cause of worsening seizures
44. A review of medication errors and compliance in ambulant patients
45. Measurement of medication compliance in a clinical setting. Comparison of three methods in patients prescribed digoxin
46. Intentional prescription nonadherence (noncompliance) by the elderly
47. Compliance declines between clinic visits
48. How often is medication taken as prescribed? A novel assessment technique
49. Why people use health services
50. Sociobehavioral determinants of compliance with health and medical care recommendations
51. Promoting compliance: The patient provider partnership
52. Patient compliance - Don't count on it
53. Overview of methods to measure and enhance patient compliance
54. Optimizing long-term patient compliance
55. Drug utilization review in ambulatory setting: State of the science and directions for outcomes research
56. A primer on drug utilization review
57. Improving prescribing patterns for the elderly through on-line drug utilization review intervention: A system linking the physician, pharmacist, and computer
58. Drug utilization 90% - A simple method for assessing the quality of drug prescribing
59. Outcomes measurements. The key to the appropriate use of pharmaceuticals
60. Using pharmacist clinical intervention data for quality improvement of medication use and physician assessment
61. Identifying and improving compliance patterns: A composite plan for health care providers